資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34144
|
| 標題: | Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy |
| 作者: | Yeh, Ming-Lun
Kuo, Hsing-Tao
Huang, Ching-, I
Huang, Chung-Feng
Hsieh, Ming-Yen
Liang, Po-Cheng
Lin, I-Hung
Hsieh, Meng-Hsuan
Lin, Zu-Yau
Chen, Shinn-Chern
Dai, Chia-Yen
Huang, Jee-Fu
Yu, Ming-Lung
Chuang, Wan-Long |
| 貢獻者: | Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div
Kaohsiung Med Univ, Coll Med, Fac Med
Kaohsiung Med Univ, Coll Med, Hepatitis Res Ctr
Kaohsiung Med Univ, Canc Res Ctr
Kaohsiung Med Univ, Ctr Liquid Biopsy
Chi Mei Med Ctr, Dept Internal Med, Div Hepatogastroenterol
Chia Nan Univ Pharm & Sci, Dept Senior Citizen Serv Management
Natl Sun Yat Sen Univ, Inst Biomed Sci
Natl Chiao Tung Univ, Coll Biol Sci & Technol |
| 關鍵字: | direct acting antivirals
hepatitis C virus
hepatocellular carcinoma
Sorafenib
survival |
| 日期: | 2021 |
| 上傳時間: | 2022-11-18 11:25:50 (UTC+8) |
| 出版者: | Wiley |
| 摘要: | Whether patients with advanced hepatocellular carcinoma (aHCC) benefit from hepatitis C virus (HCV) eradication is uncertain. We aimed to investigate whether a survival benefit was conferred by HCV eradication in aHCC patients. This retrospective cohort study enrolled 168 HCV-infected aHCC patients from April 2013 to January 2019. All patients were treated with sorafenib. Endpoints included overall survival (OS), progression free survival (PFS), and time to liver decompensation. Patients with undetectable HCV RNA exhibited reduced aspartate aminotransferase and alpha fetoprotein levels, as well as an attenuated proportion of aHCC at initial diagnosis but increased albumin and mean sorafenib daily dosing. Patients with undetectable HCV RNA exhibited significantly longer OS compared to patients with detectable or unknown HCV RNA, which was an independent factor of OS (HR: 0.56, 95% CI: 0.350-0.903,P= .017). Patients with undetectable HCV RNA also presented a trend for longer PFS (HR 0.68, 95% CI: 0.46-1.00,P= .053). The survival benefit was considered with respect to the significantly prolonged time to Child-Pugh B scores in patients with undetectable HCV RNA (HR 0.59, 95% CI: 0.38-0.92,P= .020). Patients with detectable HCV RNA at sorafenib initiation who further received direct acting antiviral therapy also had significantly longer OS (HR 0.11, 95% CI: 0.02-0.81,P= .030) and PFS (HR 0.23, 95% CI: 0.06-0.99,P= .048). In conclusion, abolishing HCV viremia preserves liver function and confers a survival benefit in advanced HCC patients on sorafenib treatment. |
| 關聯: | Kaohsiung Journal of Medical Sciences, v.37, n.2, pp.9 |
| 顯示於類別: | [Dept. of Senior Service and Health Management] Periodical Articles
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 444 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
